American Century Companies Inc. Acquires 139,246 Shares of Insulet Co. (NASDAQ:PODD)

American Century Companies Inc. raised its holdings in shares of Insulet Co. (NASDAQ:PODD) by 18.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 885,669 shares of the medical instruments supplier’s stock after purchasing an additional 139,246 shares during the quarter. American Century Companies Inc. owned 1.26% of Insulet worth $178,728,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC bought a new position in Insulet during the second quarter valued at $32,000. Sunbelt Securities Inc. bought a new position in Insulet during the first quarter valued at $29,000. UMB Bank n.a. lifted its position in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Jones Financial Companies Lllp bought a new position in Insulet during the fourth quarter valued at $40,000. Finally, CVA Family Office LLC lifted its position in Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the subject of several research reports. BTIG Research lowered their price objective on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Redburn Atlantic initiated coverage on shares of Insulet in a research note on Thursday, May 30th. They issued a “buy” rating and a $235.00 target price on the stock. OTR Global reissued a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Barclays increased their target price on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $234.00 target price on shares of Insulet in a research note on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $225.29.

Insulet Trading Up 1.2 %

NASDAQ PODD opened at $230.45 on Friday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. The company has a market capitalization of $16.14 billion, a price-to-earnings ratio of 69.83, a price-to-earnings-growth ratio of 4.02 and a beta of 1.21. The company’s 50-day simple moving average is $198.49 and its two-hundred day simple moving average is $185.28. Insulet Co. has a one year low of $125.82 and a one year high of $232.56.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period last year, the business posted $0.38 EPS. Equities analysts forecast that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.